Diagnostics M&A Deals Skyrocket in 2021 as Companies Have COVID-19 Cash to Burn
As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
Diagnostics M&A Deals Skyrocket in 2021 as Companies Have COVID-19 Cash to Burn
Published in 360Dx
Author: Kelsy Ketchum
Abstract:
As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
News
Outcome Capital Continues to Expand with the Addition of Charles Simmons
Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreResources
Outcome Capital Life Science Market Pulse, November 2024
Outcome Capital Life Science Market Pulse November 2024 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
